EUVIMEDEUVIMED entdecken
Fallbericht

Pregnancy-induced prolactinoma enlargement

M Hasebe iD, K Shibue, A Hamasaki iD

QJM: An International Journal of Medicine · 2024

DOI: 10.1093/qjmed/hcae027 ↗

Kurz gefasst

Fallbericht in der Zeitschrift QJM: An International Journal of Medicine, 2024. Verfasst von M Hasebe und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480,…. Hauptthemen laut MEDLINE: Prolactinoma, Pituitary Neoplasms, Pregnancy Complications, Neoplastic, Magnetic Resonance Imaging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 4 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A 23-year-old woman at 22 weeks’ gestation presented to our hospital with the chief complaint of a headache. Four years prior, she had been diagnosed with an 11 mm prolactinoma (Figure 1a), which manifested with galactorrhea and an elevated prolactin level (60.7 ng/ml, reference range: 3.5–32.7 ng/ml). Despite the tumor size remaining stable, her prolactin levels declined to ∼20 ng/ml after initiating treatment with cabergoline at a dose of 1 mg/week. However, she discontinued the medication on her own 6 months prior to her current presentation. Magnetic resonance imaging revealed significant tumor enlargement (19 mm), now encroaching upon the optic chiasm (Figure 1b). With persistent headaches, cabergoline treatment was restarted at 0.5 mg/week despite her pregnancy. This intervention stabilized the tumor size and alleviated her headaches. At 38 weeks of gestation, she delivered a healthy female neonate via a scheduled cesarean section. Postpartum, the cabergoline dose was incrementally increased to 3 mg/week, reducing prolactin levels to around 10 ng/ml. Follow-up imaging 1 year postpartum demonstrated a reduction in tumor size to 16 mm (Figure 1c), and 2 years postpartum, the tumor had receded to become nearly imperceptible (Figure 1d). Coronal scan of T1-weighted magnetic resonance imaging of hypothalamic–pituitary regions (a) at the initial diagnosis of a prolactinoma, (b) at the presentation of 22 weeks’ gestation, (c) 1 year postpartum, and (d) 2 years postpartum. For women with macroprolactinomas desiring to conceive, it is advisable to pursue pregnancy only after achieving normalized prolactin levels and a substantial reduction in tumor volume.1 This strategy aims to reduce the risk of tumor growth during pregnancy, which has been reported in 21.0% of cases of macroprolactinomas not treated with prior surgery or radiotherapy.2 Attaining significant tumor control with dopamine agonists before considering pregnancy is crucial.1 Dopamine agonists are not typically recommended for use during pregnancy. However, in situations where there are aggressive prolactin-secreting tumors or when a tumor is pressing on the optic nerve crossing, as seen in this case, the benefits may outweigh the risks and justify their use.3,4 Clinicians managing reproductive-aged women with macroprolactinomas must emphasize the importance of deliberate family planning and remain vigilant for the onset of symptoms, especially visual disturbances and headaches, which can indicate tumor growth during pregnancy. Masashi Hasebe (Conceptualization [lead], Data curation [lead], Supervision [lead], Writing—original draft [lead], Writing—review & editing [equal]), Kimitaka Shibue (Writing—review & editing [equal]) and Akihiro Hamasaki (Supervision [supporting], Writing—review & editing [equal]) Ethics statement: Written informed consent was obtained from the patient for the publication of this article. None declared.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProlactinomaPituitary NeoplasmsPregnancy Complications, NeoplasticMagnetic Resonance ImagingHumansFemalePregnancyAdultProlactin

Substanzen

Prolactin

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, 2-4-20 Ohgimachi, Kita-ku, Osaka 530-8480, Japan.

ORCID-Profile: M Hasebe, A Hamasaki

Zitieren

APA

Hasebe, M., Shibue, K., & Hamasaki, A. (2024). Pregnancy-induced prolactinoma enlargement. QJM: An International Journal of Medicine. https://doi.org/10.1093/qjmed/hcae027

Vancouver

Hasebe M, Shibue K, Hamasaki A. Pregnancy-induced prolactinoma enlargement. QJM: An International Journal of Medicine. 2024. doi:10.1093/qjmed/hcae027

BibTeX
@article{Hasebe2024,
  author = {Hasebe, M and Shibue, K and Hamasaki, A},
  title = {Pregnancy-induced prolactinoma enlargement},
  journal = {QJM: An International Journal of Medicine},
  year = {2024},
  doi = {10.1093/qjmed/hcae027}
}
Kostenlos starten →